Bimatoprost 0.01% or 0.03% After Latanoprost 0.005% Treatment in Glaucoma or Ocular Hypertension: Two Randomized 12-Week Trials

Friday, April 25, 2014
KIOSKS (Boston Convention and Exhibition Center)
Jonathan S. Myers, MD, Wills Eye Hospital, Philadelphia, PA, USA
Steven D. Vold, MD, Vold Vision, PLLC, Bentonville, AR, USA
Fiaz Zaman, MD, Houston Eye Associates, Houston, TX, USA
Julia Williams, Allergan Inc., Irvine, CA, USA
David A. Hollander, MD, MBA, UCLA, Irvine, CA, USA

Narrative Responses:

Purpose
To evaluate the intraocular pressure (IOP)–lowering efficacy and safety of monotherapy with bimatoprost 0.01% or 0.03% in patients treated with latanoprost 0.005% monotherapy who require additional IOP lowering for their ocular hypertension (OHT) or open angle glaucoma (OAG).

Methods
Two prospective, investigator-masked, randomized, parallel-group, multicenter studies enrolled patients with OHT or OAG who had baseline IOP of ≥20 mm Hg after ≥30 days of latanoprost 0.005% monotherapy. Following baseline measurements, patients discontinued latanoprost and were randomized to 12 weeks of study treatment (bimatoprost 0.01% QD or bimatoprost 0.01% QD plus brimonidine 0.1% TID in Study 1; bimatoprost 0.03% QD or bimatoprost 0.03% QD plus fixed-combination brimonidine 0.2%/timolol 0.5% BID in Study 2). Patient evaluations at weeks 4 and 12 included IOP and safety assessments.

Results
Primary and secondary efficacy endpoints including IOP and change from baseline IOP (at 8 am, 10 am, and 4 pm) at week 12 will be reported, as well as safety measures and adverse events for the study arms randomized to monotherapy (bimatoprost 0.01% or bimatoprost 0.03%).

Conclusion
These studies were designed to evaluate alternative monotherapies for patients who do not meet target IOP with latanoprost 0.005% alone.